These countries are most vulnerable to the emerging market storm

Trouble in paradise: For the past decade, a river of easy money rushed into emerging markets. Now that powerful force is reversing. Rising interest rates, along with trade wars, have started a stampede out of some emerging markets. The Turkish lira and Argentine peso have crashed, while China’s stock market …

Goldman Says India’s World-Beating Stock-Market Run Is Over

Goldman Sachs Group Inc. has called time on the world-beating surge in Indian stocks. The nation’s equity market looks less favorable amid elevated valuations, a potential slowdown in economic growth and upcoming elections, according to Goldman Sachs analysts, who cut India to the equivalent of a hold rating from buy. …

A Warning On Canadian Pot Stocks

Stocks of Canadian cannabis producers and sellers are on a wild run in 2018. A selection of talked about names have doubled or tripled in value the past few months, with others not far behind. Price action like that is bound to pique the interest of investors and traders who …

A.I. could spur global growth as much as the steam engine did, study shows

Artificial intelligence could contribute an additional 1.2 percent to annual gross domestic product growth for at least the next decade, according to a simulation from McKinsey Global Institute. Overall, AI could deliver $13 trillion in additional global economic activity by 2030, putting its contributions to growth on par with the …

Gene editing of dogs offers hope for treating human muscular dystrophy

Fighting fire with fire, researchers working with dogs have fixed a genetic glitch that causes Duchenne muscular dystrophy (DMD) by further damaging the DNA. The unusual approach, using the genome editor CRISPR, allowed a mutated gene to again make a key muscle protein. The feat—achieved for the first time in …

First CRISPR clinical trial backed by U.S. companies launches

The first clinical trial of CRISPR-Cas9 sponsored by U.S. companies has launched, testing the genome-editing technique in patients with the blood disorder beta thalassemia, according to an announcement posted Friday on the U.S. clinical trials website. The Phase 1/2 clinical trial, co-sponsored by Vertex Pharmaceuticals and using an experimental treatment …

The S&P 500 Might Be Forming a Dreaded ‘Double Top.’

The S&P 500 hit a new intraday all-time high on Tuesday, briefly—and barely—surpassing its previous record of 2,873 set in January. The index closed at 2,862 on Wednesday, still about 11 points under the new high-water mark. This is what technical analysts refer to as a “double top.” It’s characterized …

SEC rejects bitcoin ETFs from Proshares and Direxion

The SEC has again disapproved several proposals for a bitcoin ETF. The latest rejection involves two ETFs filed by ProShares that would track bitcoin futures contracts, another from GraniteShares, and five leveraged and inverse ETFs from Direxion. This follows on the heels of the SEC’s rejection of the Winklevloss ETF …

Corona beer maker Constellation ups bet on cannabis with $4 billion investment in Canopy Growth

Constellation Brands is upping its bet on the cannabis industry, announcing an additional $4 billion stake in Canopy Growth on Wednesday. The maker of Corona and Modelo beers in October took a 9.9 percent stake in the Canadian cannabis company. The deal included the option for future investments, giving Constellation …

Ontario scraps government monopoly, adopts private retail plan for adult-use cannabis market

Ontario’s new retail framework for recreational cannabis will start with online-only sales when legalization takes effect Oct. 17, with a network of privately owned stores expected to be in place by April 1. The new retail plan, first reported by Marijuana Business Daily, is a complete overhaul of the previous …